A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...